林业发展局警告更年期药物Veoza的肝损伤风险,需要定期监测。 FDA warns of liver injury risks with menopause drug Veozah, requiring regular monitoring.

林业发展局已发出严重警告,警告由于肝脏受伤害的危险,需使用Veozah更年期药物。 The FDA has issued a severe warning about the menopause drug Veozah due to risks of liver injury. 虽然该药物的好处仍然大于风险,但使用Veozah的妇女可能需要在治疗的头三个月进行每月血液检查,以监测肝脏健康,此后每六个月继续监测一次。 While the drug's benefits still outweigh the risks, women using Veozah may need monthly blood tests for the first three months of treatment to monitor liver health, with continued monitoring every six months thereafter. 如果发现肝脏问题,林业局建议停止药物治疗。 The FDA advises stopping the medication if liver issues are detected.